Olivia Gruder, MD
Neurology · Nashville, TNNPI 1710484167
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,655 of the $5,976 with a category attached, or 77.9%. TG Therapeutics, Inc. accounts for 95.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $5,644 and has fallen 95.3% since, to $267 in 2024.
Across 10 payments — averaging $597.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$6K
- Biogen$141
- EMD Serono, Inc.$103
Across 30 payments — averaging $4268.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$128K
What the payments were for
- Consulting fees$4,65578%
- Travel & lodging$92616%
- Food & beverage$3185%
- Education$761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 7 | $5,731 |
| Biogen | 2 | $141 |
| EMD Serono, Inc. | 1 | $103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$5,449
How this compares
$5,976 in reported general payments places this provider in the 60th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 27 | $20,605 |
| Nurtec OdtRimegepant Sulfate | 13 | $14,179 |
| Dalfampridine ErDalfampridine | 18 | $6,421 |
| Gabapentin | 46 | $977 |
| Carbamazepine ErCarbamazepine | 12 | $921 |
| Propranolol Hcl | 15 | $566 |
| Baclofen | 41 | $539 |
| Primidone | 21 | $517 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 27 | $472 |
| Memantine Hcl | 22 | $398 |
| RizatriptanRizatriptan Benzoate | 11 | $335 |
| Tizanidine Hcl | 16 | $187 |
| Amitriptyline Hcl | 19 | $153 |
| Prochlorperazine Maleate | 15 | $106 |
| Atorvastatin Calcium | 12 | $98 |
Paid to pharmacies, not to this prescriber.
Other neurology in Nashville
- Harold MosesNashville$438K
- Daniel ClaassenNashville$285K
- Francesca BagnatoNashville$167K
- Philip CharlesNashville$132K
- Benjamin HoffmanNashville$124K
- Joy DerwenskusNashville$107K
- James EatonNashville$85K
- Elizabeth FerlugaNashville$77K
- Britt StoneNashville$75K
- Lavanya NagineniNashville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.